Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK MORNING BRIEFING: Scotland-Exposed Stocks Lead Opening Declines

Mon, 08th Sep 2014 07:34

LONDON (Alliance News) - UK stocks most exposed to Scottish independence are dragging on the London market at the open Monday, after a weekend poll showing the "Yes" vote pulling ahead for the first time. RBS, Standard Life, SSE and Aberdeen Asset Management are all among the biggest blue-chip fallers.

However, it is AB Foods that is at the bottom of the FTSE 100, down 3.9%, after reiterating guidance for earnings per share to be substantially higher this year, but warning again about sugar prices and the strong pound.

Here is what you need to know at the UK market open:
----------
MARKETS
----------
FTSE 100: down 0.4% at 6,830.06
FTSE 250: down 0.7% at 15,810.54
AIM ALL-SHARE: down 0.3% at 776.80
----------
Hang Seng: down 0.4% at 25,150.81
Nikkei 225: closed up 0.2% at 15,705.11
DJIA: closed up 0.4% at 17,137.36
S&P 500: closed up 0.5% at 2,007.71
----------
GBP-USD: down at USD1.6170
EUR-USD: down at USD1.2944

GOLD: up at USD1,261.69 per ounce
OIL (Brent): down at USD100.59 a barrel

(changes since end of previous GMT day)
----------
ECONOMICS AND GENERAL
----------
Monday's Key Economic Events still to come
(all times British Summer Time)

09:30 EU Sentix Investor Confidence
13:30 Canada Building Permits
20:00 US Consumer Credit Change
----------
British Chancellor George Osborne promised Sunday that more powers would be transferred to Scotland after an opinion poll showed the Scottish independence camp ahead for the first time, days before a referendum on whether to split from Britain is due to be held. Pro-independence campaigners took a narrow lead with 51% of those surveyed in favour of leaving the 300-year-old union, while 49% were opposed. Undecided voters were excluded from the poll.
----------
Fresh fighting in eastern Ukraine on Sunday threatened to undermine a fragile ceasefire between pro-Russian separatists and government forces announced a little more than 24 hours earlier. One woman was killed and three people injured in Mariupol, after the city's eastern outskirts were attacked during the night, the city council said.
----------
UK AUG HALIFAX HOUSE PRICES RISE 0.1% ON MONTH, CONSENSUS 0.1%
----------
Ireland's construction sector activity continued to rise strongly in August, though at a slower rate than in July, survey data from Markit Economics showed. The Ulster Bank purchasing managers' index, or PMI, for the construction sector decreased to 61.4 in August from 62.6 in July. This marked the twelfth straight month of expansion in activity. A reading above 50 signals growth in construction activity.
----------
Germany's export grew more than forecast in July, while imports fell unexpectedly, data from Destatis revealed. Exports climbed 4.7% in July from June, while it was forecast to rise by 0.6%. In June, shipments rose 0.9%. Meanwhile, imports fell 1.8%, reversing the 4.5% increase in June. Imports were expected to grow by 0.2%. As a result, the trade surplus rose to seasonally adjusted EUR22.1 billion from EUR16.4 billion in June. On an unadjusted basis, the trade surplus totaled EUR23.4 billion versus EUR16.6 billion a month ago.
----------
Chinese trade surplus rose unexpectedly in August as exports surged to a record and imports unexpectedly declined, figures from China's General Administration of Customs showed. The trade surplus increased to USD49.83 billion in August from USD47.30 billion in July, with the August reading marking a 78% jump from the year-ago period. Economists had expected the trade surplus to decline from the previous month to USD 40 billion. Exports surged 9.4% year-over-year in August, a bigger increase than the 9% rise expected by economists, Nevertheless, this was slower than the 14.5% growth recorded in July. Meanwhile, imports declined 2.4% in August, dropping for the second straight month. Economists had expected imports to recover by 3% in August after the 1.6% drop in July.
----------
The Chinese Ministry of Commerce unveiled measures to make overseas investment by domestic companies easier. Only overseas investment in sensitive countries or regions, as well as in sensitive industries will need prior approval from the ministry, the Xinhua news agency reported Sunday. Sensitive countries or regions include those nations that have not established diplomatic ties with China and that are subject to United Nations sanctions, the agency said. The new measures will take effect on October 6.
----------
Japan's gross domestic product contracted a downwardly revised 7.1% on year in the second quarter of 2014, the Cabinet Office said in Monday's final reading. The reading marked the country's worst decline since the earthquake and tsunami in 2011, due in large part to a sharp decline in consumer spending following the implementation of a consumption tax hike in April. The headline figure missed forecasts for a downward revision to -7.0% after the August 13 preliminary estimate suggested a contraction of 6.8%. GDP had climbed 6.1% on year in the first quarter.
----------
Japan posted a current account surplus of JPY416.7 billion in July, the Ministry of Finance said on - down 31% on year. The headline figure was shy of forecasts for a surplus of JPY444.2 billion following the JPY399.1 billion deficit in June.
----------
BROKER RATING CHANGES
---------
JPMORGAN RAISES BARRATT DEVELOPMENTS TO 'OVERWEIGHT' ('NEUTRAL') - PT 460 (440) P
----------
BERNSTEIN CUTS MORRISON TO 'UNDERPERFORM' ('MARKET-PERFORM') - PT 140 (180) P
----------
BERNSTEIN RAISES TESCO TO 'MARKET-PERFORM' ('UNDERPERFORM') - PRICE TARGET 235 PENCE
----------
COMPANIES - FTSE 100
----------
Associated British Foods reiterated its guidance for earnings per share to be substantially higher this year, with strong operating profit from its Primark and Grocery arms and an improvement in its Ingredients business offsetting the problems in its Sugar business and a currency hit to its overseas results. The group said it expects sales for its Primark discount clothing retail arm to be 17% ahead of last year in the twelve months to 13 September on a constant currency basis and up 16% at actual exchange rates. ABF expects to take a total hit of GBP50 million to its results across all divisions due to the strength of sterling and the impact of translating overseas results into the currency.
----------
The British government has, for the first time, waded into the legal battle involving BP and payouts related to the Gulf of Mexico oil spill, saying US court rulings against the oil company raise "grave international comity concerns", the Financial Times reported Sunday. The FT cited a filing made to the US Supreme Court in which the UK government said BP had "gone to great lengths to restore the gulf coast" but was being forced to payout huge fines to individuals and business that were not affected by the spill. It warned the treatment of BP undermined confidence in fairly resolving disputes in the US and the "trust necessary for international commerce", the FT said.
----------
AstraZeneca said safety and efficacy data from its Phase IIa study of benralizumab for the treatment of chronic obstructive pulmonary disease were published in 'The Lancet Respiratory Medicine' medical journal. The study did not meet its primary endpoint, as benralizumab did not reduce the acute exacerbation rate compared with a placebo in the overall patient population. However, it did show "clinically significant improvements in lung function" in the overall population.
----------
Virgin Atlantic Airways is set to close its UK domestic airline only 18 months it was launched with a pledge to take on British Airways and to cut fares, the Sunday Times reported over the weekend. The closure of Little Red, started in March last year, will be a defeat for Richard Branson, Virgin Atlantic's founder, who said when the service was launched it would "stop BA dominating routes and driving higher prices", the paper said. Little Red started offering flights from London to three cities - Manchester, Edinburgh and Aberdeen - with the aim to then feed passengers into Virgin's long-haul network. It was created in response to the takeover of domestic carrier British Midlands Regional Ltd, known at BMI, by International Consolidated Airlines Group, the owner of BA.
----------
Old Mutual has had a GBP600.0 million takeover bid rebuffed by wealth manager Quilter Cheviot, Sky News reported late Friday. Sky News said it "understands" that the wealth manager was the subject of a recent Old Mutual bid, even though the wealth manager is considering a listing. The report said that Bridgepoint, the private equity firm which controls Quilter Cheviot, is "understood to have rejected the proposal on the grounds that it undervalued the company".
----------
The investigation being conducted by the UK's Serious Fraud Office into bribery allegations involving Rolls-Royce took a turn over the weekend, after it emerged two men arrested in dawn raids in February had their bail lifted, an indication they are likely to play no further part in the inquiry, the Sunday Times reported. Sudhir Choudrie and his son, Bhanu, were detained in February as part of a probe into bribery allegations made against the FTSE 100 aerospace company in Indonesia and China. Rolls-Royce was accused two years ago of paying USD20 million in bribes to Tommy Suharto, the son of the former Indonesian president.
----------
COMPANIES - FTSE 250
----------
Veterinary pharmaceutical business Dechra Pharmaceuticals expressed confidence in its future prospects and hiked its total dividend for the year to end-June, as it saw pretax profit rise. Dechra Pharmaceuticals proposed a total dividend of 15.40 pence, up 10% from 14.00 pence in the previous year. The company posted a pretax profit of GBP21.4 million, up from GBP12.5 million, as it saw revenue rise to GBP193.6 million from GBP189.2 million.
----------
De La Rue has been chosen by the Bank of England as its preferred bidder in the tender for its banknote printing contract. In a statement, the Bank of England said it expects to sign the contract in October, subject to completion of assurance activities in relation to De La Rue's bid, finalisation of the contract, and the final award decision by the Court of the Bank of England.
----------
Unite Group said its Unite Students division has been given planning permission for the development of a 0.8 acre site in Portsmouth city centre. The new site is set to provide accommodation for 836 students and is expected to be completed in time for the start of the 2016-17 academic year. Unite is buying the site from Portsmouth City Council and represents a GBP20 million investment by the property company, Unite said.
----------
COMPANIES - LONDON MAIN MARKET AND AIM
----------
Skyepharma said that its partner Mundipharma International Corp has announced results from a Phase III study of its Flutiform treatment for paediatric asthma at the European Respiratory Society in Munich, Germany. The study showed the efficacy and tolerability of the treatment in children with asthma between the ages of five to twelve, the company said.
----------
Stem cell therapy company ReNeuron Group said it has appointed Olav Hellebø as its new chief executive officer with immediate effect. Hellebø most recently acted as chief executive of Norwegian biotechnology company Clavis Pharma ASA, and prior to that headed UCB Pharma Ltd's global biologics franchise and Novartis AG's UK commercial operations. Michael Hunt, the chief executive since 2005, will remain on the board as chief financial officer.
----------
Charles Stanley Group warned that trading results will be materially below current market expectations when it reports half yearly results in mid-November, despite its actions to cut costs and boost income. The group said that a trading pattern of low transaction volumes hurting commission income - as well as the costs of upgrading its service and rolling out its direct-to-client proposition - put pressure on profit margins in July and August, as was the case in the first quarter. However, the group reported improving fee income and discretionary funds.
----------
Getech Group said it has won a new USD5 million proprietary services contract with the Angolan National Oil Company, Sonangol, giving it confidence of meeting current year market forecasts. In a statement, Getech, which provides data, studies and services to the oil, gas and mining exploration sectors, said it expects that most of the income from the contract will be recognised in the current financial year.
----------
COMPANIES - INTERNATIONAL
----------
Conglomerate General Electric Co has agreed to sell its Appliances business to Swedish home appliances company Electrolux AB for USD3.3 billion. According to this, GE has inked a long-term agreement with Electrolux to continue the usage of the GE Appliances brand. The transaction, which is approved by the boards of both the companies, is targeted to close in 2015.
----------
Monday's Scheduled AGMs/EGMs

Creston
BACIT
Mulberry Group
BSD Crown
----------
By Tom Waite; thomaslwaite@alliancenews.com; @thomaslwaite

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
12 Jul 2010 07:27

ReNeuron Group To Present New Data Of Lead CTX Stem Cell Line

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN), a clinical-stage stem cell business, said Monday it will present important new data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. MAIN FACTS: -The results of these studies will be pr

Read more
29 Jun 2010 07:51

ReNeuron Group FY Pretax Loss GBP6.2M On Revenue GBP31,000

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN) said Tuesday that for the year ended March 31, it made a pretax loss of GBP6.2 million on revenue of GBP31,000. MAIN FACTS: -Revenue GBP31,000 (2009: GBP93,000) -Operating loss GBP6.2 million (2009: loss GBP4.7 million) -Pretax loss GB

Read more
28 Jan 2010 13:48

Sector movers: Drug sector off colour

The pharmaceuticals sector fell back after AstraZeneca posted a 10% rise in fourth quarter earnings, but predicted 2010 revenues would be hit by the loss of exclusive rights to sell certain drugs. The company is also planning to cut 8,000 jobs from its global workforce of 63,000. While Astra falls

Read more
28 Jan 2010 11:25

Small caps round-up: Xcite, ReNeuron, CPL Resources

Shares in Xcite Energy jumped after the oil group said its subsidiary Xcite Energy Resources has concluded an agreement with BP subsidiary BP Oil International to market and sell Xcite's crude oil from the Bentley field in the North Sea. ReNeuron group climbed after the stem cell developer said Pha

Read more
11 Jan 2010 16:41

London close: Footsie gives up gains

The leading share index gave up early gains to finish only slightly higher as euphoria over strong trade figures from China in December gave way to renewed fears over recovery prospects. China's December imports jumped by 55.9% from the same month the previous year, while exports were 17.7% higher

Read more
11 Jan 2010 14:16

London afternoon: Stocks back on the climb

Leading shares, which had been surrendering early gains at the end of the morning, picked up again over the lunch time session, helped by expectations of a firm start by Wall Street. In the absence of much in the way of corporate events to attract attention, traders have been focused on broker note

Read more
11 Jan 2010 08:44

ReNeuron poised for stroke treatment trials

Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year. ReNeuron said it has submitted extra data for the UK's Gene Therapy Advisory Committee. If a successful review of the data is r

Read more
26 Nov 2009 14:45

Small caps round-up: Hampson Industries, Bezant, Tangent Comms...

Aerospace and engineering group Hampson Industries reported a 32% slump in first half profit before tax to £11m on revenue down 12% to £97m. "Although the immediate outlook for our core markets remains uncertain, present customer indications and the scale of new work in the pipeline all point to a

Read more
16 Nov 2009 11:54

Small caps round-up: Ocean Wilsons, Fortune Oil, Freshwater...

PR and marketing group Freshwater's profits fell sharply last year, but the fourth quarter saw an improvement that has continued into the current year. Pre-tax profit fell to £0.24m from £1.17m, on sales of £9.1m down from £9.5m. "Profitability improved in the second half, and we have gone into th

Read more
2 Oct 2009 15:33

ReNeuron boosted by study findings

Shares in stem cell developer ReNeuron were wanted after the company drew attention to the publication of new research using the company's ReNcell neural stem cell products. Researchers based in California have developed a safe strategy for reprogramming cells to a pluripotent (capable of affecting

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
8 Jul 2009 13:44

Sector movers: Astra lifts drug stocks after broker boost

Pharmaceutical stocks are higher after the broker Panmure Gordon said AstraZeneca was set to benefit from US rivals that produce generic alternatives to its cancer drug Casodex being too slow off the mark. AstraZeneca's slight rise is not as impressive as that of stem cell therapy developer ReNeuro

Read more
8 Jul 2009 10:55

Small caps round-up: Brainjuicer, ReNeuron, Hamworthy...

Market researcher BrainJuicer, whose clients include Unilever and Nike, posted revenue growth of about 22% for the first half and said it expects to make further progress in 2009. Stem cell therapy developer ReNeuron said clinical data on its lead CTX neural stem cell line in stroke and neurodegene

Read more
30 Jun 2009 09:00

Small caps round-up: MediaZest, Reneuron, Atlantic Coal...

Display advertising and screens provider Mediazest's pre-tax profits slide in the year as administrative expenses were too high, prompting the firm to undertake further cost cutting measures. The group also said first half of 2009 has seen a drop in activity as a consequence of the economic downt

Read more
9 Jun 2009 12:21

Angel rallies on ReNeuron deal

Angel Biotechnology rallied on news that the biopharmaceutical contract manufacturer signed a GMP manufacturing deal with ReNeuron. The value of the contract was not disclosed. The signing of deal follows on from ReNeuron's recent MHRA regulatory approval to commence a clinical trial with stem cell

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.